Axios @axios
Sales of Abbvie's blockbuster anti-inflammatory drug Humira have declined internationally, as cheaper copycats known as biosimilars gain more traction in Europe. But sales have continued to rise in the U.S. because biosimilars are locked out until 2023. https://t.co/jSKUlRuOKt — PolitiTweet.org
